REFERENCES
1. Chiu W, Hsun YH, Chang KJ, et al. Current genetic survey and potential gene-targeting therapeutics for neuromuscular diseases. Int J Mol Sci. 2020;21:9589.
2. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.
3. Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol. 2023;947:175675.
4. Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22:917-34.
5. Suzuki H, Aoki Y, Kameyama T, et al. Endogenous multiple exon skipping and back-splicing at the DMD mutation hotspot. Int J Mol Sci. 2016;17:1722.
6. Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270:3733-49.
7. Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101.
8. Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79.
9. Qian C, Klimchak AC, Szabo SM, Popoff E, Iannaccone ST, Gooch KL. Observing the clinical course of Duchenne muscular dystrophy in medicaid real-world healthcare data. Adv Ther. 2024;41:2519-30.
10. Grounds MD, Terrill JR, Al-Mshhdani BA, Duong MN, Radley-Crabb HG, Arthur PG. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. Dis Model Mech. 2020;13:dmm043638.
11. Szigyarto C. Duchenne muscular dystrophy: recent advances in protein biomarkers and the clinical application. Expert Rev Proteomics. 2020;17:365-75.
12. Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15:840-8.
13. Reinig AM, Mirzaei S, Berlau DJ. Advances in the treatment of Duchenne muscular dystrophy: new and emerging pharmacotherapies. Pharmacotherapy. 2017;37:492-9.
14. Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533-45.
15. Dadgar S, Wang Z, Johnston H, et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol. 2014;207:139-58.
16. Choi IY, Lim H, Estrellas K, et al. Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. Cell Rep. 2016;15:2301-12.
17. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.
18. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5:e13984.
19. Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30:187-200.
20. Huang HY, Lin YC, Cui S, et al. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2022;50:D222-30.
21. Han H, Shim H, Shin D, et al. TRRUST: a reference database of human transcriptional regulatory interactions. Sci Rep. 2015;5:11432.
22. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504.
23. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 (Suppl 4):S11.
24. R Core Team. R: A language and environment for statistical computing. 2013. Available from https://cran.r-project.org/bin/windows/base/ [Last accessed on 29 Dec 2025].
25. RStudio Team. RStudio: Integrated development environment for R. 2020. Available from https://posit.co/download/rstudio-desktop/ [Last accessed on 29 Dec 2025].
26. Duan Q, Reid SP, Clark NR, et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine. npj Syst Biol Appl. 2016;2:16015.
28. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901-6.
29. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28:235-42.
30. The UniProt Consortium. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. 2023;51:D523-31.
31. Davis AP, Wiegers TC, Johnson RJ, Sciaky D, Wiegers J, Mattingly CJ. Comparative toxicogenomics database (CTD): update 2023. Nucleic Acids Res. 2023;51:D1257-62.
32. Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y. CB-Dock: a web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sin. 2020;41:138-44.
33. Akiduki S, Ikemoto MJ. Modulation of the neural glutamate transporter EAAC1 by the addicsin-interacting protein ARL6IP1. J Biol Chem. 2008;283:31323-32.
34. Lim JH, Kang HM, Kim DH, et al. ARL6IP1 gene delivery reduces neuroinflammation and neurodegenerative pathology in hereditary spastic paraplegia model. J Exp Med. 2024;221:e20230367.
35. Ritchie KE, Nör JE. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 2013;338:41-6.
36. Devaiah BN, Singer DS. CIITA and its dual roles in MHC gene transcription. Front Immunol. 2013;4:476.
37. Comi C, Leone M, Bonissoni S, et al. Defective T cell fas function in patients with multiple sclerosis. Neurology. 2000;55:921-7.
38. Cao Y, Miao XP, Huang MY, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944-50.
39. Aldeeri AA, Alazami AM, Hijazi H, Alzahrani F, Alkuraya FS. Excessively redundant umbilical skin as a potential early clinical feature of Morquio syndrome and FKBP14-related Ehlers-Danlos syndrome. Clin Genet. 2014;86:469-72.
40. Aledo JC, Gómez-Fabre PM, Olalla L, Márquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome. 2000;11:1107-10.
41. Blais ME, Dong T, Rowland-Jones S. HLA-C as a mediator of natural killer and T-cell activation: spectator or key player? Immunology. 2011;133:1-7.
42. Vollmers S, Lobermeyer A, Körner C. The new kid on the block: HLA-C, a key regulator of natural killer cells in viral immunity. Cells. 2021;10:3108.
43. Nowicka-Bauer K, Malcher A, Włoczkowska O, Kamieniczna M, Olszewska M, Kurpisz MK. Evaluation of seminal plasma HSPA2 protein as a biomarker of human spermatogenesis status. Reprod Biol. 2022;22:100597.
44. Mohanty G, Jena SR, Kar S, Samanta L. Paternal factors in recurrent pregnancy loss: an insight through analysis of non-synonymous single-nucleotide polymorphism in human testis-specific chaperone HSPA2 gene. Environ Sci Pollut Res Int. 2022;29:62219-34.
45. Cobb LJ, Salih DA, Gonzalez I, et al. Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J Cell Sci. 2004;117:1737-46.
46. Ren H, Yin P, Duan C. IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop. J Cell Biol. 2008;182:979-91.
47. Rong J, Jie Y, Zhao H. m6A ‘writer’ KIAA1429 regulates the proliferation and migration of endothelial cells in atherosclerosis. Mol Biotechnol. 2023;65:1198-206.
48. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494-502.
49. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996;68:109-82.
51. Lawson T, El-Kamand S, Boucher D, et al. The structural details of the interaction of single-stranded DNA binding protein hSSB2 (NABP1/OBFC2A) with UV-damaged DNA. Proteins. 2020;88:319-26.
52. Lira MC, Rosa FD, Aiello I, et al. NCoA3 upregulation in breast cancer-associated adipocytes elicits an inflammatory profile. Oncol Rep. 2023;49:105.
53. Steele-Perkins G, Plachez C, Butz KG, et al. The transcription factor gene Nfib is essential for both lung maturation and brain development. Mol Cell Biol. 2005;25:685-98.
54. Biswas R, Bagchi A. NFkB pathway and inhibition: an overview. Comput Mol Biol. 2016;6:1. Available from: https://bioscipublisher.com/index.php/cmb/article/view/2268. [Last accessed on 25 Dex 2025].
55. Papachristodoulou A, Heidegger I, Virk RK, et al. Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression. Eur Urol. 2024;85:361-72.
56. Sinha S, Bheemsetty VA, Inamdar MS. A double helical motif in OCIAD2 is essential for its localization, interactions and STAT3 activation. Sci Rep. 2018;8:7362.
57. Xie T, Pan S, Zheng H, et al. PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression. Cancer Cell Int. 2018;18:112.
58. Glass GE, Mohammedali S, Sivakumar B, et al. Poland-Möbius syndrome: a case report implicating a novel mutation of the PLXND1 gene and literature review. BMC Pediatr. 2022;22:745.
59. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-51.
60. Zhu Y, Loukola A, Monni O, et al. PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas. Leuk Lymphoma. 2001;41:177-83.
61. Zhang X, He Y, Lee KH, et al. Rap2b, a novel p53 target, regulates p53-mediated pro-survival function. Cell Cycle. 2013;12:1279-91.
62. Jeremiah N, Ferran H, Antoniadou K, et al. RELA tunes innate-like interferon I/III responses in human T cells. J Exp Med. 2023;220:e20220666.
64. Citron BA, Saykally JN, Cao C, Dennis JS, Runfeldt M, Arendash GW. Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer’s disease. Am J Neurodegener Dis. 2015;4:40-8.
66. McKee MD, Cole WG. Chapter 2 - Bone Matrix and Mineralization. In: Glorieux FH, Pettifor JM, Jüppner HBT-PB, editors. Pediatric bone. San Diego: Elsevier; 2012. pp. 9-37.
67. Goodman SR, Johnson D, Youngentob SL, Kakhniashvili D. The spectrinome: the interactome of a scaffold protein creating nuclear and cytoplasmic connectivity and function. Exp Biol Med. 2019;244:1273-302.
68. Tang W, Shao Q, He Z, Zhang X, Li X, Wu R. Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on pan-cancer analysis. BMC Cancer. 2023;23:303.
70. Breslin A, Denniss FA, Guinn BA. SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun. 2007;363:462-5.
71. Aubrey BJ, Strasser A, Kelly GL. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med. 2016;6:a026062.
72. Shelton EL, Yutzey KE. Twist1 function in endocardial cushion cell proliferation, migration, and differentiation during heart valve development. Dev Biol. 2008;317:282-95.
73. Song X, Zhang Y, Dai E, Du H, Wang L. Mechanism of action of celastrol against rheumatoid arthritis: a network pharmacology analysis. Int Immunopharmacol. 2019;74:105725.
74. Hesterkamp T, Whittaker M. Fragment-based activity space: smaller is better. Curr Opin Chem Biol. 2008;12:260-8.
75. Sano M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology. 2001;40:947-53.
76. Jiménez A, Carrasco L, Vázquez D. Enzymic and nonenzymic translocation by yeast polysomes. Site of action of a number of inhibitors. Biochemistry. 1977;16:4727-30.
77. Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J. 2013;12:359.
78. Xing Z, Su A, Mi L, et al. Withaferin a: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment - pharmacology and mechanisms. Drug Des Devel Ther. 2023;17:2909-29.
79. Hahm ER, Kim SH, Singh SV. Withaferin A inhibits breast cancer-induced osteoclast differentiation. Mol Carcinog. 2023;62:1051-61.
80. Patra JK, Das G, Lee S, Kang S, Shin H. Selected commercial plants: a review of extraction and isolation of bioactive compounds and their pharmacological market value. Trends Food Sci Technol. 2018;82:89-109.
81. Deshaies M, Lamari N, Ng CKY, Ward P, Doohan FM. The impact of chitosan on the early metabolomic response of wheat to infection by Fusarium graminearum. BMC Plant Biol. 2022;22:73.
82. Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97:e2304-14.
83. Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy. JMA J. 2021;4:232-40.
84. Wasala NB, Hakim CH, Chen SJ, Yang NN, Duan D. Questions answered and unanswered by the first CRISPR editing study in a canine model of Duchenne muscular dystrophy. Hum Gene Ther. 2019;30:535-43.
85. Zhao B, Wang L, Hu P, et al. Fusing higher and lower-order biological information for drug repositioning via graph representation learning. IEEE Trans Emerg Topics Comput. 2024;12:163-76.
86. Agatsuma T, Ogawa H, Akasaka K, et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem. 2002;10:3445-54.
87. Schulte TW, Akinaga S, Murakata T, et al. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol Endocrinol. 1999;13:1435-48.
88. Zhou H, Qiao K, Gao Z, Vederas JC, Tang Y. Insights into radicicol biosynthesis via heterologous synthesis of intermediates and analogs. J Biol Chem. 2010;285:41412-21.
89. Rice CA, Colon BL, Chen E, Hull MV, Kyle DE. Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae. PLoS Negl Trop Dis. 2020;14:e0008353.
90. Islam T, Rahman MR, Aydin B, Beklen H, Arga KY, Shahjaman M. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19. Eur J Pharmacol. 2020;887:173594.
91. Turanli B, Karagoz K, Bidkhori G, et al. Multi-omic data interpretation to repurpose subtype specific drug candidates for breast cancer. Front Genet. 2019;10:420.
92. Sail V, Hadden MK. Chapter eighteen - notch pathway modulators as anticancer chemotherapeutics. Annu Rep Med Chem. 2012;47:267-80.
93. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S. Withania somnifera (Ashwagandha) and withaferin a: potential in integrative oncology. Int J Mol Sci. 2019;20:5310.
94. Straughn AR, Kakar SS. Withaferin a: a potential therapeutic agent against COVID-19 infection. J Ovarian Res. 2020;13:79.
95. Das R, Rauf A, Akhter S, et al. Role of Withaferin a and its derivatives in the management of alzheimer’s disease: recent trends and future perspectives. Molecules. 2021;26:3696.
96. Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol. 2012;84:1282-91.
97. Radzka J, Łapińska Z, Szwedowicz U, Gajewska-Naryniecka A, Gizak A, Kulbacka J. Alternations of NF-κB signaling by natural compounds in muscle-derived cancers. Int J Mol Sci. 2023;24:11900.
98. Zhang W, Zhuang X, Wu C, et al. Apigenin inhibits tumor angiogenesis by hindering microvesicle biogenesis via ARHGEF1. Cancer Lett. 2024;596:216961.
99. Dormán G, Flachner B, Hajdú I, András C. Target identification and polypharmacology of nutraceuticals. In: Gupta RC, Lall R, Srivastava A, Editors. Nutraceuticals. Elsevier Inc.; 2016. pp. 263-86.
100. Jantan I, Haque MA, Arshad L, Harikrishnan H, Septama AW, Mohamed-Hussein ZA. Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. J Nutr Biochem. 2021;93:108634.
101. Yang M, Lin L, Scartelli C, et al. Inhibition of Sars-Cov-2 viral replication and in vivo thrombus formation by a novel plant flavonoid. Blood. 2021;138:3144.
103. Laoudj-Chenivesse D, Carnac G, Bisbal C, et al. Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med. 2005;83:216-24.
104. Hangül C, Karaüzüm SB, Akkol EK, et al. Promising perspective to facioscapulohumeral muscular dystrophy treatment: nutraceuticals and phytochemicals. Curr Neuropharmacol. 2021;19:2276-95.
105. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood. 2007;109:2727-35.
106. Cohen TV, Cohen JE, Partridge TA. Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response. Neuromuscul Disord. 2012;22:648-58.
107. Cascão R, Fonseca JE, Moita LF. Celastrol: a spectrum of treatment opportunities in chronic diseases. Front Med. 2017;4:69.
108. Xu S, Feng Y, He W, et al. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res. 2021;167:105572.
109. Wang Z, Zhai Z, Du X. Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells. Exp Ther Med. 2017;14:819-24.
110. Gwag T, Ha K, Shin H, et al. Application of a heat shock protein inducer to remedy for an atrophied muscle cell: a basic research for ISS/JEM onboard experiment. Trans JSASS Aerospace Tech Japan. 2014;12:Pp_7-Pp_10.
111. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson’s disease. BMC Neurosci. 2009;10:109.
112. Wu M, Zhang Y. Integrated bioinformatics, network pharmacology, and artificial intelligence to predict the mechanism of celastrol against muscle atrophy caused by colorectal cancer. Front Genet. 2022;13:1012932.
113. Kori M, Arga KY, Mardinoglu A, Turanli B. Repositioning of anti-inflammatory drugs for the treatment of cervical cancer sub-types. Front Pharmacol. 2022;13:884548.
114. Jadamba E, Shin M. A systematic framework for drug repositioning from integrated omics and drug phenotype profiles using pathway-drug network. Biomed Res Int. 2016;2016:7147039.
115. Fuzo CA, Martins RB, Fraga-Silva TFC, et al. Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation. bioRxiv. 2021;bioRxiv:2021.04.20.439992.
116. Kumar R, Khandelwal N, Chander Y, et al. Emetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibitinginteraction of viral mRNAwith eIF4E: an in vitro study. bioRxiv. 2020;bioRxiv:2020.11.29.401984.
117. Wang X, Li M, Yin J, et al. Emetine dihydrochloride alleviated radiation-induced lung injury through inhibiting EMT. J Cell Mol Med. 2023;27:3839-50.
119. Savva K, Zachariou M, Bourdakou MM, Dietis N, Spyrou GM. Network-based stage-specific drug repurposing for Alzheimer’s disease. Comput Struct Biotechnol J. 2022;20:1427-38.
120. Wang Y, Li C, Gu J, et al. Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signalling. J Cell Mol Med. 2020;24:941-53.
121. Petrillo S, Pelosi L, Piemonte F, et al. Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway. Hum Mol Genet. 2017;26:2781-90.
122. Messina S, Vita GL, Aguennouz M, et al. Activation of NF-κB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol. 2011;30:16-23.
123. Donovan J, Elvire Vandenborne KH, Sweeney L, et al. Move DMD results: effects of edasalonexent, an NF-kB inhibitor, in 4 to 7 year old patients with Duchenne Muscular dystrophy (P3.210). Neurology. 2017;88:P3.210.
124. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn’s disease biopsies. Biochem Biophys Res Commun. 2004;322:778-86.
125. Khalili N, Karimi A, Moradi MT, Shirzad H. In vitro immunomodulatory activity of celastrol against influenza a virus infection. Immunopharmacol Immunotoxicol. 2018;40:250-5.
126. Cascão R, Vidal B, Raquel H, et al. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev. 2012;11:856-62.
127. Trott A, West JD, Klaić L, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell. 2008;19:1104-12.
